THE WOODLANDS, Texas, July 21, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company, today announced the filing of a provisional patent application on test and drug targeting designs using its identified protein biomarkers and protein biomarker footprints for early detection, monitoring, and staging of a broad range of diseases including neurodegenerative diseases and various forms of cancer.
The Company's intellectual property portfolio currently does not include any issued patents. This new application, in conjunction with other pending patents, provisional patent applications, licensing agreements, and proprietary technologies, increases Power3's IP platform. Power3 is continuing to pursue an aggressive intellectual property strategy, thereby continuing its position as a leader in Proteomics.
Dr. Ira L. Goldknopf, the Company's Chief Scientific Officer said, "We have been able to create these designs because our identified protein biomarkers and footprints are based on definitive patient's clinical samples and therefore we have determined how to use them for clinical disease characterization. This is a step forward in the science of Proteome-diagnostics."
About Power3 Medical Products, Inc.
Power3 Medical Products, www.Power3Medical.com, is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The Company's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company's identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company is in a strong competitive position with over 250 identified biomarkers of human disease and operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.